Wolfe Research analyst Doug Schenkel downgraded Myriad Genetics (MYGN) to Peer Perform from Outperform.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- China announces stimulus measures, Disney reports Q2 beat: Morning Buzz
- Myriad Genetics price target lowered to $18 from $29 at Craig-Hallum
- Myriad Genetics price target lowered to $7 from $16 at UBS
- Myriad Genetics price target lowered to $10 from $19 at Raymond James
- Wells downgrades Myriad Genetics, sees ‘show-me story’ after miss